A legal challenge against Gilead Sciences’ (Nasdaq: GILD) patent application for the combination of sofosbuvir and velpatasvir has been launched by Médecins Sans Frontières (MSF).
The therapy, which was approved last year in the USA and in Europe, is marketed as Epclusa.
The company has faced numerous similar patent challenges this year, including multiple aggressive actions from USA-based non-profit Initiative for Medicines, Access & Knowledge (I-MAK) and, in Europe, from MSF.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze